Alps Advisors Inc. raised its position in Bluebird Bio Inc. (NASDAQ:BLUE) by 25.0% during the second quarter, Holdings Channel reports. The fund owned 51,898 shares of the company’s stock after buying an additional 10,368 shares during the period. Alps Advisors Inc.’s holdings in Bluebird Bio were worth $2,247,000 at the end of the most recent reporting period.
Several other hedge funds have also bought and sold shares of BLUE. OMERS ADMINISTRATION Corp boosted its stake in Bluebird Bio by 1.7% in the first quarter. OMERS ADMINISTRATION Corp now owns 6,000 shares of the company’s stock worth $255,000 after buying an additional 100 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Bluebird Bio by 31.6% in the first quarter. Legal & General Group Plc now owns 2,895 shares of the company’s stock worth $123,000 after buying an additional 695 shares in the last quarter. UBS Asset Management Americas Inc. boosted its stake in shares of Bluebird Bio by 0.8% in the first quarter. UBS Asset Management Americas Inc. now owns 157,666 shares of the company’s stock worth $6,701,000 after buying an additional 1,194 shares in the last quarter. Teachers Advisors Inc. boosted its stake in shares of Bluebird Bio by 5.5% in the first quarter. Teachers Advisors Inc. now owns 46,048 shares of the company’s stock worth $1,957,000 after buying an additional 2,416 shares in the last quarter. Finally, BlackRock Group LTD boosted its stake in shares of Bluebird Bio by 11.2% in the first quarter. BlackRock Group LTD now owns 24,672 shares of the company’s stock worth $1,049,000 after buying an additional 2,493 shares in the last quarter.
Bluebird Bio Inc. (NASDAQ:BLUE) traded down 3.91% during midday trading on Thursday, reaching $66.41. The company’s stock had a trading volume of 1,494,643 shares. The company’s 50-day moving average is $59.55 and its 200 day moving average is $49.06. The firm’s market capitalization is $2.47 billion. Bluebird Bio Inc. has a 52 week low of $35.37 and a 52 week high of $106.95.
Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share for the quarter, missing the consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The business had revenue of $1.55 million for the quarter, compared to analyst estimates of $2.01 million. During the same quarter last year, the company posted ($1.57) EPS. Bluebird Bio’s quarterly revenue was down 68.6% on a year-over-year basis. Analysts expect that Bluebird Bio Inc. will post ($6.18) earnings per share for the current fiscal year.
A number of brokerages have commented on BLUE. Maxim Group set a $100.00 price target on Bluebird Bio and gave the stock a “buy” rating in a research report on Thursday. Goldman Sachs Group Inc. reaffirmed a “buy” rating and set a $135.00 price target on shares of Bluebird Bio in a research report on Thursday, August 18th. Zacks Investment Research raised Bluebird Bio from a “sell” rating to a “hold” rating in a research report on Monday, August 8th. BTIG Research reaffirmed a “buy” rating and set a $72.00 price target on shares of Bluebird Bio in a research report on Wednesday, June 29th. Finally, Jefferies Group reaffirmed a “positive” rating and set a $80.00 price target on shares of Bluebird Bio in a research report on Thursday, July 14th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $90.25.
In other news, insider David Davidson sold 1,000 shares of the stock in a transaction dated Friday, July 15th. The shares were sold at an average price of $45.08, for a total transaction of $45,080.00. Following the completion of the sale, the insider now owns 10,600 shares in the company, valued at $477,848. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Sullivan sold 2,807 shares of the stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $45.04, for a total transaction of $126,427.28. Following the sale, the insider now owns 4,656 shares of the company’s stock, valued at approximately $209,706.24. The disclosure for this sale can be found here. Insiders own 3.50% of the company’s stock.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bluebird Bio Inc. (NASDAQ:BLUE).
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.